| First Published on Clinicaltrials.gov: |
4/21/2009 |
| Status: |
Ongoing, But Not Recruiting |
| ClinicalTrials.gov ID: |
NCT00886977 |
| Sponsor: |
Yoshino Neurology Clinic |
| Purpose: |
The efficacy and safety are evaluated when YAM80 is administered orally to the patients of Amyotrophic Lateral Sclerosis (ALS). |
| Phase: |
II |
| Treatment Type: |
Orally available in pill form |
| Trial Type: |
Open label |
| Estimated Enrollment: |
25 |
| Eligibility: |
25 years to 65 years old. Both genders. No healthy volunteers. |
| Details: |
Drug: YAM80 Oral administration, 2 to 6 mg, once a day for 24 weeks. |
| Collaborator(s): |
|
| Location(s): |
|
| Primary Investigator: |
Hiide Yoshino, M.D. Yoshino Neurology Clinic |
| Contact: |
|
| Trial Protocol as Published on Clinicaltrials.gov: |
|
| ALS Forum: |
|